Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation
- PMID: 21292771
- DOI: 10.1182/blood-2010-10-311894
Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation
Abstract
Hastening posttransplantation immune reconstitution is a key challenge in human leukocyte antigen (HLA)-haploidentical hematopoietic stem-cell transplantation (HSCT). In experimental models of mismatched HSCT, T-regulatory cells (Tregs) when co-infused with conventional T cells (Tcons) favored posttransplantation immune reconstitution and prevented lethal graft-versus-host disease (GVHD). In the present study, we evaluated the impact of early infusion of Tregs, followed by Tcons, on GVHD prevention and immunologic reconstitution in 28 patients with high-risk hematologic malignancies who underwent HLA-haploidentical HSCT. We show for the first time in humans that adoptive transfer of Tregs prevented GVHD in the absence of any posttransplantation immunosuppression, promoted lymphoid reconstitution, improved immunity to opportunistic pathogens, and did not weaken the graft-versus-leukemia effect. This study provides evidence that Tregs are a conserved mechanism in humans.
Similar articles
-
CD56-enriched donor cell infusion after post-transplantation cyclophosphamide for haploidentical transplantation of advanced myeloid malignancies is associated with prompt reconstitution of mature natural killer cells and regulatory T cells with reduced incidence of acute graft versus host disease: A pilot study.Cytotherapy. 2017 Apr;19(4):531-542. doi: 10.1016/j.jcyt.2016.12.006. Epub 2017 Jan 25. Cytotherapy. 2017. PMID: 28131632 Clinical Trial.
-
Immunoselection and clinical use of T regulatory cells in HLA-haploidentical stem cell transplantation.Best Pract Res Clin Haematol. 2011 Sep;24(3):459-66. doi: 10.1016/j.beha.2011.05.005. Epub 2011 Jun 29. Best Pract Res Clin Haematol. 2011. PMID: 21925099 Clinical Trial.
-
Role of antithymocyte globulin and granulocyte-colony stimulating factor-mobilized bone marrow in allogeneic transplantation for patients with hematologic malignancies.Biol Blood Marrow Transplant. 2009 Feb;15(2):266-73. doi: 10.1016/j.bbmt.2008.11.029. Biol Blood Marrow Transplant. 2009. PMID: 19167687 Clinical Trial.
-
Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.Dan Med Bull. 2007 May;54(2):112-39. Dan Med Bull. 2007. PMID: 17521527 Review.
-
Regulatory T cells in allogeneic hematopoietic stem cell transplantation: From the lab to the clinic.Cell Immunol. 2019 Dec;346:103991. doi: 10.1016/j.cellimm.2019.103991. Epub 2019 Oct 3. Cell Immunol. 2019. PMID: 31607390 Review.
Cited by
-
Haploidentical age-adapted myeloablative transplant and regulatory and effector T cells for acute myeloid leukemia.Blood Adv. 2021 Mar 9;5(5):1199-1208. doi: 10.1182/bloodadvances.2020003739. Blood Adv. 2021. PMID: 33646302 Free PMC article.
-
T-cell depletion: from positive selection to negative depletion in adult patients.Bone Marrow Transplant. 2015 Jun;50 Suppl 2:S11-3. doi: 10.1038/bmt.2015.88. Bone Marrow Transplant. 2015. PMID: 26039200
-
Regulatory immune cells in transplantation.Nat Rev Immunol. 2012 May 25;12(6):417-30. doi: 10.1038/nri3227. Nat Rev Immunol. 2012. PMID: 22627860 Review.
-
FOXP3+ regulatory T cells and their functional regulation.Cell Mol Immunol. 2015 Sep;12(5):558-65. doi: 10.1038/cmi.2015.10. Epub 2015 Feb 16. Cell Mol Immunol. 2015. PMID: 25683611 Free PMC article. Review.
-
Advancing Allogeneic Hematopoietic Stem Cell Transplantation Outcomes through Immunotherapy: A Comprehensive Review of Optimizing Non-CAR Donor T-Lymphocyte Infusion Strategies.Biomedicines. 2024 Aug 14;12(8):1853. doi: 10.3390/biomedicines12081853. Biomedicines. 2024. PMID: 39200317 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials